Last reviewed · How we verify
CKD-333 Tab.
At a glance
| Generic name | CKD-333 Tab. |
|---|---|
| Also known as | Test |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers (PHASE1)
- Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers (PHASE1)
- Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers (PHASE1)
- Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers (PHASE1)
- Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet (PHASE3)
- Pharmacokinetics and Safety Profile of CKD-333 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-333 Tab. CI brief — competitive landscape report
- CKD-333 Tab. updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI